We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.5%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.17B
AUM Growth
+$187M
Cap. Flow
-$13.4M
Cap. Flow %
-0.62%
Top 10 Hldgs %
27.68%
Holding
163
New
13
Increased
39
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$28M
2
IRTC icon
iRhythm Holdings
IRTC
+$17.5M
3
PBYI icon
Puma Biotechnology
PBYI
+$13.4M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$10.8M
5
MOH icon
Molina Healthcare
MOH
+$10.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$37.9M
2
HUM icon
Humana
HUM
+$31.9M
3
HOLX
Hologic
HOLX
+$19.1M
4
MDT icon
Medtronic
MDT
+$12.7M
5
WBA
Walgreens Boots Alliance
WBA
+$6.74M

Sector Composition

Rank Sector Weight
1 Healthcare 80.49%
2 Financials 3.75%
3 Consumer Discretionary 0.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
76
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.12M 0.42%
244,000
-63,000
-21% -$1.91M
FPRX
77
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$8.91M 0.41%
217,700
+20,700
+11% +$650K
SRGA
78
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$8.87M 0.41%
65,000
– –
RARX
79
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$8.76M 0.4%
600,000
– –
RARE icon
80
Ultragenyx Pharmaceutical
RARE
$2.55B
$8.68M 0.4%
163,000
+2,500
+2% +$148K
CHRS icon
81
Coherus Oncology
CHRS
$196M
$8.52M 0.39%
638,400
-55,500
-8% -$734K
TXMD icon
82
TherapeuticsMD
TXMD
$24M
$8.46M 0.39%
32,000
– –
ZLAB icon
83
Zai Lab
ZLAB
$2.62B
$8.44M 0.39%
+312,500
New +$8.72M
HQY icon
84
HealthEquity
HQY
$8.75B
$8.35M 0.39%
165,000
+114,000
+224% +$5.31M
CLSD
85
DELISTED
Clearside Biomedical
CLSD
$8.17M 0.38%
62,333
– –
AXGN icon
86
Axogen
AXGN
$2.5B
$7.74M 0.36%
400,000
+25,000
+7% +$420K
AIMT
87
DELISTED
Aimmune Therapeutics
AIMT
$7.26M 0.34%
293,000
– –
ADAP
88
DELISTED
Adaptimmune Therapeutics
ADAP
$7.17M 0.33%
875,000
– –
REGN icon
89
Regeneron Pharmaceuticals
REGN
$80.8B
$7.15M 0.33%
16,000
– –
ACAD icon
90
Acadia Pharmaceuticals
ACAD
$5.03B
$6.86M 0.32%
182,000
+8,000
+5% +$260K
OBSV
91
DELISTED
ObsEva SA Ordinary Shares
OBSV
$6.84M 0.32%
840,000
– –
SGEN
92
DELISTED
Seagen Inc. Common Stock
SGEN
$6.8M 0.31%
125,000
+25,000
+25% +$1.28M
CRVS icon
93
Corvus Pharmaceuticals
CRVS
$1.17B
$6.74M 0.31%
422,600
– –
STE icon
94
Steris
STE
$23.1B
$6.54M 0.3%
74,000
+1,500
+2% +$127K
TTPH
95
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$6.5M 0.3%
47,500
+12,600
+36% +$1.69M
BPMC
96
DELISTED
Blueprint Medicines
BPMC
$6.03M 0.28%
+86,500
New +$4.62M
GTHX
97
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$5.97M 0.28%
240,000
-72,188
-23% -$1.33M
CMTA
98
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$5.83M 0.27%
+345,000
New +$5.64M
ARNA
99
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.48M 0.25%
+215,000
New +$4.93M
MRUS
100
DELISTED
Merus
MRUS
$5.46M 0.25%
275,000
-127,000
-32% -$2.03M
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Rock Springs Capital Management held 163 positions worth $2.17B, up 9.5% from $1.98B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management's Q3 2017 filing shows 13 new, 39 increased, 20 reduced and 16 closed positions. Its largest new stake was iRhythm Holdings: 386,000 shares worth $20M. The largest sale was Allergan plc, an estimated $37.9M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 80% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q3 2017 buy was iRhythm Holdings: 386,000 shares worth $20M.
  • Rock Springs Capital Management added most to UnitedHealth in Q3 2017, an estimated $28M increase.
  • Rock Springs Capital Management's biggest Q3 2017 reduction was Medtronic, cutting an estimated $12.7M.
  • Rock Springs Capital Management fully exited Allergan plc in Q3 2017, selling an estimated $37.9M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $2.17B portfolio in Q3 2017.
  • Rock Springs Capital Management opened 13 new positions and closed 16 in Q3 2017.
  • Rock Springs Capital Management's portfolio value rose 9.5% quarter-over-quarter to $2.17B.

Based on Rock Springs Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.